Agenus vs Karyopharm Therapeutics
Karyopharm Therapeutics is the larger business, with $146m of revenue in fiscal 2025 against $114m for Agenus (1.3 times as much). Agenus grew faster (10.4% against 0.6%). Agenus kept more of each dollar of sales as profit: a net margin of -0.1% against -134.2%.
| Latest fiscal year | AgenusAGEN, 2025 | Karyopharm TherapeuticsKPTI, 2025 |
|---|---|---|
| Revenue | $114m | $146m |
| Revenue growth | 10.4% | 0.6% |
| Net income | −$101,000 | −$196m |
| Operating margin | -17.7% | -62.1% |
| Net margin | -0.1% | -134.2% |
| Return on equity | — | — |
| Free cash flow | −$77.2m | −$75.4m |
| Cash | $3.0m | $60.5m |
| Total debt | $45.5m | $94.8m |
| Debt to equity | — | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 81 | 228 |
| Market value | $284m | $2.0m |
| Price vs our value range | — | — |
| Moat score | 34 (Weak) | 8 (Weak) |
| Insider trades, 12 months | 0 buys, 0 sales | 0 buys, 21 sales |